KLRS

Kalaris Therapeutics
KLRS

7.57 USD
+0.45
6.32%
At close Updated Dec 10, 4:00 PM EST
Pre-market
After hours
7.45
-0.12
1.59%
1 day
6.32%
5 days
36.64%
1 month
57.71%
3 months
66.37%
6 months
145.78%
Year to date
-26.86%
1 year
-35.57%
5 years
-99.17%
10 years
-98.7%
 

About: Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

Healthcare Biotechnology
0
Funds holding %
of 7,505 funds
Explore Fund Trends
0
Analysts bullish %
of 1 analysts
See Analyst Outlook
–
Positive news %
of articles
Check Journalist POV
Price charts implemented using Lightweight Charts™